AstraZeneca

Strategic intent

AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines, primarily in Oncology, Rare Diseases, and BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology). [17, 30]

Key market signals

• 2026-01: Announced a major strategic collaboration with CSPC Pharmaceuticals to develop therapies for obesity and type 2 diabetes, involving a $1.2 billion upfront payment and potential milestones of $3.5 billion. [39]
• 2026-01: Acquired Modella AI, an artificial intelligence company, to enhance its oncology research and development capabilities. [23, 26]
• 2025-06: Settled "pay-for-delay" antitrust claims related to the drug Seroquel XR for over $50 million. [63]
• 2025-03: Announced the acquisition of Belgian biotech company EsoBiotec for up to $1 billion to enhance its cancer treatment capabilities. [23, 26]
• 2024-05: Set a strategic ambition to achieve $80 billion in total revenue by 2030, planning to launch at least 20 new medicines. [3, 43]

Financial health

• 2025 Full Year Revenue: $58.7 billion, an increase of 9%. [14]
• 2025 Full Year Core EPS: $9.16, an increase of 11%. [14]
• Q1 2026 Total Revenue: $15.29 billion, an 8% increase at constant exchange rates. [1, 4, 8]

Impact & compliance

Legal & risks

Within the last 24 months, AstraZeneca has faced several legal and regulatory challenges. In June 2025, the company settled "pay-for-delay" antitrust claims related to its drug Seroquel XR for over $50 million. [63] There is an ongoing investigation in China concerning alleged illegal activities, in

Classifications

🔒 Proprietary analysis

Proprietary Analysis — available with full access

Want the full analysis?

Get access to strategic fit scoring, cultural fit analysis, full forensic detail, and alignment dimensions.